FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790005971> ?p ?o ?g. }

• W2790005971 endingPage "157" @default.
• W2790005971 startingPage "149" @default.
• W2790005971 abstract "Anti-T lymphocyte globulin Fresenius (rATG-F; ATG-Fresenius) and antithymocyte globulin (thymoglobulin), which are included in transplant protocols, are used to reduce the risk of chronic graft-versus-host disease (cGVHD) or suppress allograft rejection. Available clinical studies have been conducted in heterogenous patient populations and with different administration protocols including stem cell sources. Additionally, the pharmacokinetics of ATG is variable, and the clinically effective dose of rATG-F, in particular, is not exactly known. The aim of the study was to investigate the clinical outcomes of acute myeloid leukemia (AML) patients who underwent hemopoietic peripheral stem cell transplantation from full-matched sibling donors and given two different doses of r-ATG-F.This was a single-center, retrospective chart review conducted between July 2005 and July 2016. Sixty-nine consecutive AML patients who underwent transplant with fludarabine- and busulfan-based conditioning were included in the study. Patients in Group 1 received 15 mg/kg body weight rATG-F to 2013 (n = 46), and Group 2 received 30 mg/kg of rATG-F dose begining in 2013 to reduce to cGVHD (n = 23). Cyclosporine and methotrexate were used to treat acute GVHD (aGVHD) prophylaxis. Outcome parameters were compared between the groups.Although the recommended dose r-ATG-F had led to a decrease in the cumulative incidence of cGVHD (27 [58.7%] vs. 8 [34.8%]; p = .03), it also increased the infection rate at 1 year (3 [6.5%] vs. 4 [17.4%]; p = .02). The two groups were similar in terms of engraftment time, aGVHD, relapse, nonrelapse mortality, and rATG-F-related toxicity. A Cox regression model revealed that aGVHD III-IV was associated with increased nonrelapse mortality at 1 year (hazard ratio = 18.2; 95% confidence interval, 1.667-199.255; p = <.02). No patients developed rATG-F-related severe adverse events (Common Terminology Criteria grade 4 or 5).Dose difference of rATG-F did not influence survival parameters; however, increasing the dose to 30 mg/kg seems to be effective for reducing cGVHD with an increase in infection rate requiring close monitoring of infections in AML patients who received myeloablative fludarabine/busulfan conditioning." @default.
• W2790005971 created "2018-03-29" @default.
• W2790005971 creator A5014824633 @default.
• W2790005971 creator A5048152848 @default.
• W2790005971 creator A5059187260 @default.
• W2790005971 creator A5061145219 @default.
• W2790005971 creator A5065419547 @default.
• W2790005971 creator A5080832885 @default.
• W2790005971 creator A5084404798 @default.
• W2790005971 creator A5088903983 @default.
• W2790005971 creator A5090902373 @default.
• W2790005971 date "2018-09-01" @default.
• W2790005971 modified "2023-10-01" @default.
• W2790005971 title "Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning" @default.
• W2790005971 cites W1887439754 @default.
• W2790005971 cites W1980914191 @default.
• W2790005971 cites W1981025559 @default.
• W2790005971 cites W1985176183 @default.
• W2790005971 cites W1985779366 @default.
• W2790005971 cites W1988034903 @default.
• W2790005971 cites W1996893745 @default.
• W2790005971 cites W2030068889 @default.
• W2790005971 cites W2039808932 @default.
• W2790005971 cites W2051239881 @default.
• W2790005971 cites W2057664415 @default.
• W2790005971 cites W2069377065 @default.
• W2790005971 cites W2087581408 @default.
• W2790005971 cites W2091661505 @default.
• W2790005971 cites W2093010852 @default.
• W2790005971 cites W2106781384 @default.
• W2790005971 cites W2107272865 @default.
• W2790005971 cites W2107611068 @default.
• W2790005971 cites W2120504920 @default.
• W2790005971 cites W2121844342 @default.
• W2790005971 cites W2136669587 @default.
• W2790005971 cites W2162824285 @default.
• W2790005971 cites W2164885965 @default.
• W2790005971 cites W2209448786 @default.
• W2790005971 cites W2233354089 @default.
• W2790005971 cites W2307073326 @default.
• W2790005971 cites W2519901822 @default.
• W2790005971 cites W2520776671 @default.
• W2790005971 cites W2525939690 @default.
• W2790005971 cites W2581469447 @default.
• W2790005971 cites W869527191 @default.
• W2790005971 doi "https://doi.org/10.1016/j.hemonc.2018.01.004" @default.
• W2790005971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29474820" @default.
• W2790005971 hasPublicationYear "2018" @default.
• W2790005971 type Work @default.
• W2790005971 sameAs 2790005971 @default.
• W2790005971 citedByCount "1" @default.
• W2790005971 countsByYear W27900059712019 @default.
• W2790005971 crossrefType "journal-article" @default.
• W2790005971 hasAuthorship W2790005971A5014824633 @default.
• W2790005971 hasAuthorship W2790005971A5048152848 @default.
• W2790005971 hasAuthorship W2790005971A5059187260 @default.
• W2790005971 hasAuthorship W2790005971A5061145219 @default.
• W2790005971 hasAuthorship W2790005971A5065419547 @default.
• W2790005971 hasAuthorship W2790005971A5080832885 @default.
• W2790005971 hasAuthorship W2790005971A5084404798 @default.
• W2790005971 hasAuthorship W2790005971A5088903983 @default.
• W2790005971 hasAuthorship W2790005971A5090902373 @default.
• W2790005971 hasBestOaLocation W27900059711 @default.
• W2790005971 hasConcept C120665830 @default.
• W2790005971 hasConcept C121332964 @default.
• W2790005971 hasConcept C126322002 @default.
• W2790005971 hasConcept C141071460 @default.
• W2790005971 hasConcept C2776694085 @default.
• W2790005971 hasConcept C2776755627 @default.
• W2790005971 hasConcept C2777408962 @default.
• W2790005971 hasConcept C2777630719 @default.
• W2790005971 hasConcept C2778461978 @default.
• W2790005971 hasConcept C2778729363 @default.
• W2790005971 hasConcept C2779263901 @default.
• W2790005971 hasConcept C2779378344 @default.
• W2790005971 hasConcept C2779972918 @default.
• W2790005971 hasConcept C2780611847 @default.
• W2790005971 hasConcept C2780882860 @default.
• W2790005971 hasConcept C2781059491 @default.
• W2790005971 hasConcept C2909675724 @default.
• W2790005971 hasConcept C2911091166 @default.
• W2790005971 hasConcept C61511704 @default.
• W2790005971 hasConcept C71924100 @default.
• W2790005971 hasConcept C88879693 @default.
• W2790005971 hasConcept C90924648 @default.
• W2790005971 hasConceptScore W2790005971C120665830 @default.
• W2790005971 hasConceptScore W2790005971C121332964 @default.
• W2790005971 hasConceptScore W2790005971C126322002 @default.
• W2790005971 hasConceptScore W2790005971C141071460 @default.
• W2790005971 hasConceptScore W2790005971C2776694085 @default.
• W2790005971 hasConceptScore W2790005971C2776755627 @default.
• W2790005971 hasConceptScore W2790005971C2777408962 @default.
• W2790005971 hasConceptScore W2790005971C2777630719 @default.
• W2790005971 hasConceptScore W2790005971C2778461978 @default.
• W2790005971 hasConceptScore W2790005971C2778729363 @default.
• W2790005971 hasConceptScore W2790005971C2779263901 @default.
• W2790005971 hasConceptScore W2790005971C2779378344 @default.
• W2790005971 hasConceptScore W2790005971C2779972918 @default.

• next